This New Company Believes Psychedelics Can Treat Dementia
There is currently no known cure for dementia, but Return Health CEO Dr. James Kuo says psychedelics offer “unprecedented” potential.
There is currently no known cure for dementia, but Return Health CEO Dr. James Kuo says psychedelics offer “unprecedented” potential.
This week in psychedelic business news: Cybin inhales; atai Life Sciences expands; DEA grants new psilocybin license; and FDA backs ketamine.
Researchers say there are several ways classic psychedelics could, directly and indirectly, lead to improved cardiometabolic health.
Food and Drug Administration grants psychedelic biotechnology company PharmaTher orphan drug designation for ketamine to treat complex regional pain syndrome.
Silo Wellness CEO Douglas K. Gordon tells Psychedelic Spotlight that this is a “crucial” step toward “the mainstream acceptance of psychedelics and overall de-stigmatization of mushrooms, by way of the functional category.”
“As traditional treatment has proven inadequate at both the individual and public health level, the Commonwealth has a responsibility to research alternative options,” the bill’s sponsors write in a memo.
Planting, cultivating, purchasing, transporting, distributing, possessing these plants and fungi will be the lowest law enforcement priority for the city.
This week in psychedelic business news: Enveric Biosciences uses AI to identify viable psychedelic drug candidates; Novamind launches end-of-life palliative care program; and PharmaTher tests ketamine to treat Parkinson’s Disease.
A new study describes the Pacific Northwest as “by far the best place in America to go looking for psychedelic mushrooms.”
The sacred entheogen was also excluded from Seattle’s resolution to decriminalize natural psychedelics.
End of content
End of content
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.